Table 1.
Baseline characteristics of enrolled patients with HCC
| Variable | Value, n=44 (%) |
|---|---|
| Age (year) | 57 ± 8.9 |
| Sex male/female | 40 (90.9%)/4 (9.1%) |
| BMI | 25.0 ± 3.3 |
| Drinking no/yes | 15 (34.1%)/29 (65.9%) |
| HBsAg negative/positive | 7 (15.9%)/37 (84.1%) |
| HCV negative/positive | 39 (88.6%)/5 (11.4%) |
| Time interval from radical (hepatectomy to advanced recurrence) ≤ 1 year/> 1 year | 24 (54.5%)/20 (45.5%) |
| Liver cirrhosis no/yes | 10 (22.7%)/34 (77.3%) |
| Number of intrahepatic lesions ≤ 3/>3 | 21 (47.7%)/23 (52.3%) |
| PVTT classification | |
| No portal vein tumor thrombosis | 37 (84.1%) |
| VP2 | 1 (2.3%) |
| VP3 | 4 (9.1%) |
| VP4 | 2 (4.5%) |
| Extrahepatic metastases | |
| No | 21 (47.7%) |
| Yes | 23 (52.3%) |
| Bone metastases | 5 (11.4%) |
| Lung metastases | 7 (15.9%) |
| Lymph node metastases | 3 (6.8%) |
| Abdominal metastases | 5 (11.4%) |
| Diaphragmatic metastases | 3 (6.8%) |
| BCLC staging at recurrence B/C | 15 (34.1%)/29 (65.9%) |
| Ascites no/yes | 42 (95.5%)/2 (4.5%) |
| AFP (≤ 400 ng/mL) | 38 (86.4%) |
| Child-Pugh classification A/B | 40 (90.9%)/4 (9.1%) |
| ECOG performance 0/1 | 35 (79.5%)/9 (20.5%) |
| ALT (U/L) | 32.1 ± 23.6 |
| AST (U/L) | 36.6 ± 23.1 |
| ALB (g/L) | 41.0 ± 5.8 |
| Total bilirubin level (mg/dL) | 15.0 ± 6.9 |
BMI body mass index, HBsAg hepatitis B surface antigen, HCV hepatitis C virus, PVTT portal vein tumour thrombosis, BCLC Barcelona Clinic Liver Cancer Group, AFP alpha-fetoprotein, ECOG Eastern Cooperative Oncology Group, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB albumin